Diagnosis and dynamic assessment of persistent
Differentiated thyroid cancer (DTC), including papillary, follicular and Hürthle cell types, accounts for nearly 95% of all thyroid carcinomas. The concept of DTC recurrence or persistence after surgery is still difficult to define due to its indolent nature. The recurrent or persistent tumors in this guideline refer to new lesions or residual tumors found during the follow-up after initial treatments.
Basic principles of diagnosis
The role of multidisciplinary team (MDT) should be emphasized during the diagnosis of prmDTC. A task force of specialists with complementary expertise (endocrinology, surgery, nuclear medicine, radiology, pathology, oncology, molecular diagnostics, and epidemiology) should be included in the MDT management of prmDTC. The diagnosis or further managements of prmDTC which may include surgical managment, radioiodine-131 ( 131 I) therapy, thyroid stimulating hormone (TSH) suppressive therapy, as well as molecular targeted therapy (or being enrolled in certain clinical trial) or radiation therapy, etc., should be tailored according to comprehensive consideration of MDT.
Diagnostic methods
Laboratory tests, imaging studies and pathological examinations are recommended in the diagnosis of prmDTC ( Table 1) .
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Multidisciplinary treatment of prmDTC

Basic principles of treatment
Treatment options for prmDTCs usually include surgical resection, 131 I therapy of lesions that can uptake 131 I, external beam radiation therapy, active follow-up under L-T4 suppression therapy and other options (e.g., targeted medicines, radiofrequency or ethanol ablation). Among them, surgery should be the first choice for resectable lesions with surgical indications.
Surgical management
PrmDTCs are commonly seen in clinical practice, approximately 95% of which occur in the neck (1) . Since the difficulty and risk of reoperation increase significantly, the risks and benefits of surgery must always be balanced when selecting reoperation. Surgery should be performed by experienced specialists, and frequently even under multidisciplinary collaboration.
Preoperative clinical assessment
Preoperative clinical assessment includes the review of previous treatments, current status of the disease and vital organ function, which are the basis for the decision regarding intervention and extent of revision surgery. Structural lesions are required as a target for a surgical revision approach, therefore, imaging evaluation is of the utmost importance to surgeons to identify and localize the structural lesions ( Table 3 ).
Principles of surgical treatment for prmDTC
The timing and extent of surgery are the most important issues which should be considered when the surgical management of prmDTC is decided. In general, the goal of revision surgery should be to try to cure or control the disease, improve survival, and preserve the function of the vital organs as far as possible ( Table 4 ). a , The most important and difficult decision for these patients is the timing of the operation. At present, it is commonly accepted that the patient can be closely followed up when the lesion is less than 8 mm in the central compartment and <10 mm in the lateral compartment, otherwise, reoperation should be considered (1-10). Preoperative fine needle aspiration (FNA) diagnosis is an important step in preoperative evaluation to avoid unnecessary reoperations. The threshold of 8 mm (central) and 10 mm (lateral) in the smallest dimension signifies disease sufficiently macroscopic to be potentially dangerous if it were to grow, and amenable to FNA as well as surgical localization if it were to be targeted for excision(1-4,9,10). In the decision-making of surgery, the following factors should also be considered (1, 2, 8, 9) : location of the lesion (whether it is adjacent to the important structures), doubling time of Tg (11), whether a positive result is shown on 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) imaging, the extent of previous operation, complications, and whether the primary lesion is a highly malignant subtype. For revision surgery, it may be a standardized lymph node dissection (1-5,9,10) or a limited operation (2,12,13). b , The incidence of temporary and permanent recurrent laryngeal nerve injury during reoperation is 1.5%−22.2% and 0.3%−6.4%, respectively (14-16), and the incidence of temporary and permanent hypoparathyroidism during reoperation is 6.5%−46.3% and 9.5%, respectively (15) (16) (17) . The recurrent laryngeal nerve monitoring in such operations plays an important role in reducing nerve injury and improving the safety of the operation (18-21). The time of nerve repair may be different between patients (21-23). Parathyroid glands should be carefully identified, rescued and preserved in situ or auto-transplanted into other locations, such as the sternocleidomastoid (1) (2) (3) (4) (5) . c , The extent of surgical resection for such lesions has been controversial, but the removal of visible tumors is very important to control local recurrence of tumor and prolong the survival of patients (24). d , 33%−61% of thyroid cancers that invade the surrounding vital structures have recurrent laryngeal nerve invasion (24-27). Studies have shown that recurrent laryngeal nerve involvement is not an independent risk factor for survival (25), residual trace lesions do not increase the local recurrence rate and reduce the survival rate (26,27). Therefore, the nerve should be preserved as far as possible (1,4,28), and if not, the affected nerve should be removed and reconstructed (1, 4, 28, 29) . Of course, when determining the surgical approach, the contralateral recurrent laryngeal nerve function and distant metastases status should also be considered in order to balance the risks and benefits of surgery. e , Airway/digestive tract (laryngeal trachea/esophageal) involvement is more serious situation, and over half of disease-specific deaths are related to airway obstruction and bleeding (28). For such patients, there are different options in surgery (1,2,28,30), when partial esophageal/tracheal/laryngectomy can be carried out, it can not only ensure adequate resection margins, but also avoid serious complications caused by more extensive resection, however, postoperative adjuvant therapies such as RAI treatment and radiotherapy are generally needed (1, 28) . f , Reconstruction may be required in the treatment of cervical vascular involvement (28), although severe invasions to the major blood vessels of the neck by differentiated thyroid cancers (DTCs) are rare (31). The involvement of internal jugular veins by metastatic lesions is the most common (32 36.
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131 I therapy
131 I therapy is one of the important adjuvant postoperative treatment modalities for prmDTC patients. It can reduce the risks of tumor recurrence, metastasis and death in high risk population (1, 2) , and significantly improve the 5-and 10-year survival for high-risk DTC patients with iodineavid lesions (3) (4) (5) (6) (7) (8) (9) . 131 I therapy is recommended in patients with iodine-avid prmDTC lesions, and should be repeated at an interval of 6−12 months as long as the lesions continue to concentrate radioiodine and respond clinically. In addition, cumulative radioiodine activities, balance between benefits and risks, and patient preferences, are relevant to 131 I therapy decisionmaking. Patients with TSH stimulation and iodine preparation, whose lesions no longer concentrate 131 I or respond to 131 I therapy, are identified as radioactive iodine refractory DTC (RAIR-DTC) in four basic ways: 1) the malignant metastatic lesion does not ever concentrate RAI (no uptake outside the thyroid bed at the first therapeutic WBS); 2) the tumor tissue loses the ability to concentrate RAI after previous evidence of RAI-avid disease (in the absence of stable iodine contamination); 3) RAI is concentrated in some lesions but not in others; and 4) disease progresses despite significant concentration of RAI (10).
Clinical assessment before 131 I therapy
Clinical information, as well as the status exactly before 131 I therapy should be considered for tailoring the management of prmDTC ( Table 5 ). Further surgical consultation should be advised if a patient has lesions which might be amenable to surgery. While in terms of the clinical information, evaluation of the response to previous therapeutics is critical for subsequent 131 I therapy of prmDTC, for instance, a previous 131 I unresponsive patient would be unlikely to benefit from another repeated 131 I therapy. (11, 12) . Currently, thyrogen is not approved by CFDA. b , Diagnostic WBS (Dx-WBS) can be used for identifying radioiodine-avid lesions, tailoring dosage of 131 I, and predicting the efficacy of 131 I therapy (1). c , BRAF V600E mutation is the most common oncogenic mutation and related to aggressive disease, recurrence and mortality. BRAF V600E mutation in isolation or in combination with TERT mutation appears to be associated with more aggressive tumor behavior, and more likely to be refractory to 131 I therapy (1,13,14).
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Management of 131 I therapy for prmDTC
Indications and dose determination of 131 I therapy for prmDTC are addressed in terms of the sites of metastases ( Table 6 ). (1,2), and 131 I adjuvant therapy after lymphadenectomy for DTC relapse is associated with better progression-free survival (PFS) in patients with Tg-on ≥1 ng/mL (3). b , Most radioiodine-avid pulmonary metastases from DTC can obtain partial or complete remission after 131 I therapy (1, 4) . For patients with responsive radioiodine-avid metastases, 131 I therapy should be repeated every 6−12 months, and complete remission can commonly be achieved in patients with micrometastases (5-8). Radioiodine-avid macronodular metastases may be treated with 131 I and 131 I may be repeated if benefits of structural or serum Tg/TgAb reduction have been observed, whereas complete remission is uncommon and the survival remains poor (2). It's unclear whether the benefits of 131 I therapy could be gained in patients with non-iodine-avid pulmonary metastases (9,10). c , Although 131 I therapy is rarely curative, it can be recommended for patients with radioiodine-avid bone metastases, as some benefits may be obtained, such as stable disease, tumor reduction, and survival improvement (1, 2, 6, 11) . Other local therapies also should be considered for those unresectable bone metastases, including external beam radiotherapy, endovascular embolization, bisphosphonate therapy, and vertebroplasty. d , Surgical resection and external beam radiotherapy are the main therapeutic methods for brain metastases. For the radioiodine-avid brain metastases, 131 I therapy can be considered. And if 131 I therapy is employed, concomitant glucocorticoid therapy would be recommended to minimize the radioiodine-induced inflammatory response. e , Tg(+) 131 I (−) refers to the status in the absence of imaging evidence of structural lesions [anatomic imaging and 131 I-whole body scan (WBS)], with significantly elevated serum Tg levels or rapidly rising serum Tg (2). So far, no survival advantages had been documented under the empiric 131 I therapy in such cases. f , There are insufficient data to support the utilization of recombinant human thyroid stimulating hormone (rhTSH) in prmDTC patients. It may be considered as an alternative to thyroid hormone withdrawal in elder patients who could not withstand hypothyroidism, or mount an adequate endogenous TSH response (1, 2, 12) . g , Avoiding iodine exposure, a low-iodine diet (<50 μg/d) before 131 I administration is recommended (1,2,12 ). h , There are three approaches to determining the therapeutic doses of 131 I: empiric fixed dosage, dosage determined by the upper limit of blood and body dosimetry, and quantitative lesional dosimetry. Currently, empiric dosimetric method is the most commonly used method (1,2,12,13). i , Dosimetric methods are often reserved for patients with unusual situations, such as children, the elderly or renal insufficiency (1, 2, 12, 13) . Empirically administered 131 I activities exceeding 150 mCi should be avoided in patients over age 70 years. 131 I is a relatively safe treatment method. Currently, there is no recommendation for the upper limit of single or cumulative 131 I doses based on prospective clinical studies. However, according to previous studies, the risk of radiation-related adverse events may be associated with the increasing cumulative 131 I dose and the treatment times (13). j , There are few data to support the efficacy of 131 I therapy for brain metastases, so no appropriate dosage could be recommended (1, 2, 14) . k , Empiric (100−200 mCi) 131 I therapy may be considered in patients with significantly elevated serum Tg levels (≥10 ng/mL), and undetectable structural disease which is unrevealed by anatomic imaging, 131 I-WBS and/or 18 FDG-PET/CT. Besides, the 131 I therapy should be stopped when there is no benefit showed after the empiric therapy (2). l , For individualized TSH suppression, please refer to 2.4.
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TSH suppression therapy
Strategy for TSH suppression therapy
For prmDTC that expresses TSH receptor, TSH suppression therapy is important in postoperative management of differentiated thyroid cancer. It has been realized the optimal degree of TSH suppression varies. An individually tailored approach to deciding TSH targets in prmDTC patients considering risk of side effects has been raised ( Table 7) .
3.
Haugen, BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26: 1-133.
4.
Diessl S, Holzberger B, Mäder U, et al. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2012;76:586-92.
5.
Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010;20:135-46.
6.
Carhill AA, Litofsky DR, Ross DS, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012. J Clin Endocrinol Metab 2015;100:3270-9.
7.
Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 2014;43: 401-21.
8.
Management of adverse effects of TSH suppression therapy
When TSH has to be suppressed below the normal range (i.e. subclinical thyrotoxicosis) for a long period, especially below 0.1 mU/L, it may cause adverse effects (AEs) ( Table 8 ).
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Long-term cardiovascular mortality in patients with 1,2) . b , The initial treatment period refers to within one year after the persistent/recurrent and metastatic differentiated thyroid cancer (prmDTC) being treated with surgery and/or radioactive iodine (3, 4) . c , The long-term follow-up period refers to one year after the prmDTC being treated with surgery and/or radioactive iodine (3, 4) . TSH suppression goals may not be uniform and should be adjusted according to results of surveillance (5-8). 
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External beam radiation therapy
External beam radiation therapy (EBRT) is an effictive and safe local therapy with benefit to local control and palliative care for prmDTC. EBRT, stereotactic radiation therapy (SBRT) and other local therapies can be used for symptomatic, weight-bearing, key site metastasis, and oligo-metastasis ( Table 9 ). (6, 7) . c , In the case of DTC lung metastases, EBRT or SBRT mainly applies to: 1) Single or oligo-metastasis (the definition of oligo-metastasis is not uniformly standardized, and it is generally considered that the number of metastases is ≤3−4); and 2) Lung metastases that do not intake iodine (8) . d , EBRT or SBRT can be mainly considered for symptomatic skeletal metastases or those that are asymptomatic in weight-bearing sites. The main role is to relieve the pain symptoms, reduce the risk of pathological bone events, and improve the quality of life (9,10). e , EBRT or SBRT is one of the main treatments for brain metastases regardless of the number and size of lesions, or the iodine intake status. Once brain metastases are diagnosed, disease-specific mortality is very high (67%), with median survival of 12.4 months. Survival can be significantly improved by neurosurgical resection. With the development of radiotherapy techniques, SBRT can achieve similar results to neurosurgery (11-13). Common adverse effects reported include skin toxicity, hypertension, gastrointestinal toxicity, proteinuria, fatigue, thyroidstimulating hormone inhibitory disorders, and impaired thyroid function. Before treatment, comprehensive assessment of certain risk factors that may increase the risk of adverse effects and necessary intervention to control concomitant diseases are recommended. For adverse effects during treatment, multidisciplinary consultation should be considered to protect important organs, improve the quality of life, and maximize the effects of targeted drugs. If the degree of adverse reactions is low and the function of important organs is well, the sustained targeted therapy is recommended to obtain the maximum curative effect and survival benefit from targeted drugs; if grade 3−4 adverse effects or the damage of important organs occur, the dose reduction or drug discontinuation should be promptly adopted until the weakening or disappearance of adverse effects, and then the therapy should restart from a lower dose.
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